Showing 1081-1090 of 1635 results for "".
- Johnson & Johnson Vision Launches the UK’s First Free Nationwide Recycling Program for all Contact Lenseshttps://modernod.com/news/johnson-johnson-vision-launches-the-uks-first-free-nationwide-recycling-program-for-all-contact-lenses/2476189/Johnson & Johnson Vision has launched the Acuvue Contact Lens Recycle Program, the UK’s first free nationwide program that enables consumers to easily recycle their contact lenses and the blister and foil packaging after use. The program is available to all soft contact lens wearers reg
- Healthe Named One of the Nation’s 20 Hottest Health Start-Upshttps://modernod.com/news/healthe-named-one-of-the-nations-20-hottest-health-start-ups/2476213/Healthe, an eye health company that develops products and technology to block ultra-violet and high-energy visible blue light, announced that it was selected by THE OBSERVER as one of the nation’s hottest digital health companies. The list focuses on non-coastal, start-ups from the Midwest, South
- Imprimis Pharmaceuticals Changes Name to Harrow Healthhttps://modernod.com/news/imprimis-pharmaceuticals-changes-name-to-harrow-health/2476233/Imprimis Pharmaceuticals announced it has formally changed its name to Harrow Health and began trading as “HROW” on the NASDAQ Capital Markets on January 2, 2019. “Our new name reflects our business model of c
- EyePoint Pharmaceuticals Added to NASDAQhttps://modernod.com/news/eyepoint-pharmaceuticals-added-to-nasdaq/2479607/EyePoint Pharmaceuticals announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). EyePoint’s addition to the NBI will become effective prior to market open on Monday, December 24, 2018. The NASDAQ Biotechnology Index is designed to track the perform
- OD-OS Releases Intuitive Iridotomy Treatment with the Navilas 577s Retina Laserhttps://modernod.com/news/od-os-releases-intuitive-iridotomy-treatment-with-the-navilas-577s-retina-laser/2479613/OD-OS has released a software update for its Navilas 577s retinal laser system (version 3.5) that incorporates a new intuitive anterior segment treatment mode for Laser Peripheral Iridotomy (LPI). The new LPI treatment mode supports the therapy of narrow-angle glaucoma and thus can contribute to
- University of Dayton Researcher Named on Second Patent for Device to Provide Better Relief for Glaucoma Patientshttps://modernod.com/news/university-of-dayton-researcher-named-on-second-patent-for-device-to-provide-better-relief-for-glaucoma-patients/2479616/Khalid Lafdi, University of Dayton Wright Brothers Endowed Chair in Nanomaterials, was named on a second patent for a medical drainage device mainly for glaucoma patients that also could be used for drainage in the ears, brain, or chest or to provide access to larger veins or arteries, according
- Opternative Changes Names to Visibly To Better Reflect Eye Care Industry Partnershipshttps://modernod.com/news/opternative-changes-names-to-visibly-to-better-reflect-eye-care-industry-partnerships/2479622/Opternative announced that it has changed its name Visibly to better represent the eye care industry, according to a company news release. “We understand that our previous company name, Opternative, carried a negative connotation in the eye care industry and positioned the brand as a
- Wills Eye Hospital’s Training in Ophthalmology Voted #1 Top Eye Residency Program in Nationhttps://modernod.com/news/wills-eye-hospitals-training-in-ophthalmology-voted-1-top-eye-residency-program-in-nation/2479623/The Wills Eye at Jefferson Residency Program in Philadelphia has been voted the #1 medical education training program in ophthalmology in the nation, according to Doximity.com. The Wills Eye Hospital faculty serve as the department of Ophthalmology at Thomas Jefferson
- Prospective Study for NaturalVue Multifocal Demonstrates Decreased Refractive Error Change in Fast-Progressing Myopic Childrenhttps://modernod.com/news/prospective-study-for-naturalvue-multifocal-demonstrates-decreased-refractive-error-change-in-fast-progressing-myopic-children/2479681/Thomas Aller, OD, presented updated findings from a prospective clinical trial of NaturalVue (etafilcon A) 1 Day Multifocal Contact Lenses at a briefing for media and industry leaders at the American Academy of Optometry (AAO) Conference in San Antonio on November 9. The NaturalVue portfolio of p
- Nicox Postpones Nasdaq Listing Due to Market Volatilityhttps://modernod.com/news/nicox-postpones-nasdaq-listing-due-to-market-volatility/2479717/Nicox SA announced that due to the extreme volatility of the financial markets, it has decided to postpone its dual listing on Nasdaq, concluding that it would not be in the interest of their existing shareholders at this time, according to a company news release. The purpose of a Nasdaq l